Most Read

BTD for IBI351 (GFH925) has been granted to treat advanced non-small cell lung cancer (NSCLC) patients with KRASG12C mutation who have undergone at least one prior line of

Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. It targets both GPRC5D, a novel drug target that is on some normal cells but overexpressed

Cilta-cel is a BCMA-directed and genetically modified autologous T-cell immunotherapy that involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR), which detects

The regulatory acceptance of application for marketing authorisation of tislelizumab is to treat first-line unresectable or metastatic HCC patients. The humanised IgG4 anti-PD-1 monoclonal antibody tislelizumab has been

The company submitted the vaccine candidate to prevent meningococcal disease, which is caused by the most common serogroups, in individuals aged 10 to 25 years. MenABCWY combines the

Olpruva is a prescription medicine which has been approved as an oral suspension to treat UCD patients with deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic

Under the deal terms, Hikma will have an exclusive right to develop and market toripalimab injection in all its Middle East and North Africa (MENA) markets. Additionally, the

NexoBrid is indicated to remove eschar in paediatric and adult patients with deep-partial and full-thickness thermal burns without surgery. Japan is claimed to be the world’s first country

The treatment is intended for such patients who have previously received two or more lines of systemic therapy. The JNDA filing is backed by the multicentre, open-label Phase